On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
New in Diabetes Care: dropout from diabetic foot ulcer offloading trials is not random. Slower walking and depressive symptoms predict who leaves (AUC 0.81) — and a lower-burden smart boot kept people engaged. Attrition is signal, not noise.
Now published in Surgery: one clinician used conversational AI to vibe-code three interactive data platforms (local, national, and global), translating 15 years of amputation evidence into public tools in under a week at essentially no cost.
Three new papers converge on a two-cent idea: the neutrophil percentage-to-albumin ratio (NPAR) measures the balance between inflammatory injury and nutritional reserve — tracking both how bad the diabetic foot is now and how the patient fares over years. Plus a clear-eyed look at why AI-driven precision nutrition isn't here yet, and what it will take.
Windy Cole and colleagues propose a master-protocol basket trial that borrows oncology's tissue-agnostic playbook for hard-to-heal wounds — testing a single mechanism-targeted therapy across diabetic foot and venous leg ulcers under one Bayesian, sham-controlled design. We've spent a decade framing the diabetic foot like cancer; here, the trial architecture grows up to match.
The World Cup isn't the only global tournament underway. Thanks to Anica Badanjak and Anela Novak's new Croatian translation, the IWGDF Guidelines now reach patients in a native language on every inhabited continent on Earth — every single one.
Two diabetic foot data engines published the same day on two continents. STEADY (US) is a 5,000-patient, AI-enabled real-world registry; DARE-DiaFoot (Italy) is a deep, multi-instrumental phenotyping protocol that quietly studies remission. One is the census, the other the core sample. Together with EURODIALE, the U.S. Wound Registry, and the National Diabetes Foot Care Audit, they sketch a blueprint for finally measuring what we manage.
Notes from the Beaumont Multidisciplinary Diabetic Foot Symposium in Dublin (18 June 2026) — a true toe-and-flow gathering across vascular surgery, podiatry, endocrinology and infectious diseases, where the watchword was remission, not cure.
Amputated tissue from the sea cucumber Psolus fabricii healed its own wounds and kept living in plain, non-sterile seawater for more than three years. Jobson et al. in Science Advances on "natural tissue immortality" — and why a wound-healing surgeon can't look away.
Forty years of the Malvern Diabetic Foot Meeting. Thirty years of mine. One last bow from Andrew Boulton in the chair. A look back at the long arc — from a Benedictine priory in 1085 to Joslin in 1928 to DFCon in 2000 to ALPS in 2020 — and a look forward to DFCon 26, DFUpdate, traveling fellowships, and the next generation already climbing the hill.
Yu and colleagues from Ken Muneoka's group show that sequential FGF2 then BMP2 treatment flips an adult mouse digit amputation from fibrosis to regeneration — rebuilding the distal phalanx with a growth plate, plus a parallel response that regenerates a synovial joint complex with tendon, ligament, and a sesamoid-like bone. The regeneration-competent cells are already in our wound beds. We just have to learn what to say to them.
